Butorphanol
A mixed opioid agonist-antagonist analgesic used for moderate-to-severe pain, including migraine headaches and labor pain. It activates kappa opioid receptors while acting as a partial antagonist at mu receptors, providing pain relief with a lower risk of physical dependence than pure mu agonists. It is available as a nasal spray and injectable solution.
น้ำหนักโมเลกุล
327.5000 g/mol
LogP
3.80
TPSA
43.70 Ų
Lipinski RO5
ผ่าน
ด้านการรักษา
กลไกการออกฤทธิ์
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
โครงสร้าง 2 มิติ
Cite this structure
Embed this structure
SMILES
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
InChI
InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
Molecular Formula
C21H29NO2
HBD / HBA
2 / 3
พันธะที่หมุนได้
2
อะตอมหนัก
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
A mixed opioid agonist-antagonist analgesic used for moderate-to-severe pain, including migraine headaches and labor pain. It activates kappa opioid receptors while acting as a partial antagonist at mu receptors, providing pain relief with a lower risk of physical dependence than pure mu agonists. It is available as a nasal spray and injectable solution.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Butorphanol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL33986. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5361092. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="butorphanol"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/butorphanol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/butorphanol/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/butorphanol/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="butorphanol"></drugfyi-drug>